To evaluate whether CAFs expressing Tr-CAF markers could inhibit tumor progression, we investigated the correlation between the CAF-specific immunohistochemical (IHC) staining levels for these 4 CAF markers; CXCL14, ADAMDEC1, EDNRB, and PROCR, and the clinical outcomes of colorectal cancer patients. Here, ADAMDEC1 is linked to neoplasm.